NCT03144661View on ClinicalTrials.gov

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

June 10, 2020

Study Completion Date

June 10, 2020

Conditions
Hepatocellular Carcinoma (HCC)CholangiocarcinomaEsophageal CancerNasopharyngeal CancerOvarian CancerSolid Tumors
Interventions
DRUG

INCB062079

In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.

Trial Locations (6)

1000

Institut Jules Bordet, Brussels

1200

Cliniques Universitaires Saint-Luc, Brussels

3000

University Hospital (UZ) Leuven, Leuven

10065

Memorial Sloan Kettering Cancer Center, New York

35294

University of Alabama, Birmingham

43614

University of Toledo Medical Center, Toledo

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY